Welcome To BTX Online !   

Hybrimune Hybridoma Production System

More Views


Hybrimune Hybridoma Production System
Advanced electrofusion system for fast, efficient cell fusion in hybridoma production, hybrid cell formation or dendritic-tumor cell fusions


Product Item # Price  
Hybrimune Electrofusion System (N. America) 47-0300N   View Price
Hybrimune Electrofusion Generator Only (N. America) 47-0305N   View Price
Login/Register to shop in US only.
All others please Login/Register or contact us for local pricing/quotes.

 

 

Details

The Hybrimune Hybridoma Production System is an advanced electrofusion system for fast, efficient cell fusion in hybridoma production, hybrid cell formation, and dendritic-tumor cell fusions.

Yield improvements of 10 fold or more compared to standard PEG fusion

The Hybrimune system includes an innovative fusion chamber design, proprietary BTXpress® Cytofusion medium and sophisticated, tri-phasic electric field pulses that quickly position cells and disrupt cell membranes for maximum cell fusion efficiency with short cycle-times and minimal heating or turbulence for excellent cell viability. In addition, Hybrimune delivers a cell alignment waveform which is a patented sequence that enhances hybridoma yield.

The Hybrimune system consists of a user-friendly, programmable waveform generator controlled through the User-Interface Application Software running on a Windows-based computer system (not included). The fusion chamber uses coaxial electrodes designed for optimal electric field stimulation, independent of bath height. In this way, pulse parameters defined with the low volume optimization chamber are directly applicable for the large volume production chamber. The optimization chamber includes a transparent bottom for microscope viewing during the process optimization. BTXpress Cytofusion medium is a specially formulated, low conductivity solution for robust cell fusion efficiency.

The Hybrimune boasts a gradual increase in AC amplitude to compress the cells for maximal cell-cell contact. The DC pulse is then applied. The researcher has the option of doing multiple pulses of different voltages and duration if required. A final AC waveform holds the cells in place and stabilizes the fusion as the force is gradually reduced. The waveform generator is fully-programmable for pulse parameter optimization to maximize efficiency and cell viability.

A computer is required for the application software but is not included in the system.

The Hybrimune is intended For Research Use Only.  Not for use in diagnostic, pre-clinical, or clinical procedures.

 Included Items

Item # Name Included Items
47-0300N Hybrimune Electrofusion System (N. America)  Hybrimune waveform generator, 2 ml and 9 ml coaxial chambers, BTXpress Cytofusion Medium C, user interface software, cables and manual. Requires Windows based laptop or PC (not included)
47-0300NINT Hybrimune Electrofusion System Hybrimune waveform generator, 2 ml and 9 ml coaxial chambers, BTXpress Cytofusion Medium C, user interface software, cables and manual. Requires Windows based laptop or PC (not included)
47-0305N Hybrimune Electrofusion Generator Only (N. America) Hybrimune Electrofusion Generator only

 

Use of the Hybrimune device is subject to an annual license agreement between Cellectis bioresearch and the purchaser. Please contact Cellectis at cytopulse@cellectis.com for further details.

 

WAVEFORM SPECIFICATIONS 

The Hybrimune Waveform Generator is programmed using the Application Software. The following parameters are available:

 

Pulse Function Constant, linear, non-linear
Pulse Amplitude 100 - 1000 V
Pulse Width Range 20 – 1000 ms
AC Start Peak Range 5 - 75 Vs
AC Stop Peak Range 5 - 75 V
AC Frequency 0.2 to 2.0 MHz
AC Duration 0 to 60 s

 

FUSION CHAMBER SPECIFICATIONS

The optimization and production chambers have been engineered to have identical electrical characteristics to facilitate direct scale-up to production once pulse parameters have been optimized. In addition the small chamber has a transparent bottom to permit visualization of the cell alignment by inverted or regular microscope.

 

Parameters Optimization Chamber Production Chamber
Volume 2 ml 9 ml
Outer ID 45.72 mm 45.72 mm
Inner OD 38.10 mm 38.10 mm
Gap 3.81 mm 3.81 mm
Well Height 5 mm 18 mm
Inner/Outer Radius 0.8333 0.8333
  • Hybridoma production
  • Hybrid cell formation
  • Dendritic-tumor cell fusions
Item # Product
47-0030 Hybrimune 2 ml Coaxial Chamber for optimization
47-0020 9 ml Coaxial Chamber for production
47-0001 BTXpress Cytofusion Medium C, 500 ml volume
47-0302 Hybrimune Chamber Cable
47-0301 Hybrimune User Interface Application Software

 

Hybrimune User's Manual

 

Hybrimune Application Note

 

REFERENCES

 

Darveau, A, et al. Efficient preparation of human monoclonal antibody-secreting heterohybridomas using peripheral B lymphocytes cultured in the CD40 system. J Immunol Meth. 1993;159:139-143.

 

Hui, SW, Stenger, DA. Electrofusion of cells: hybridoma production by electrofusion and polyethylene glycol. Methods Enzymol. 1993;220:212-227.https://www.ncbi.nlm.nih.gov/pubmed/8350755

 

James K, Bell GT. Human monoclonal antibody production. Current status and future prospects.
J ImmunolMethods. 1987;100:5-40.

 

Jaroszeski MJ, Gilbert R, Heller R. Detection and Quantitation of Cell-Cell Electrofusion Products by Flow Cytometry. AnalBiochem. 1994;216:271-275.

 

Köhler G and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. J Immunol. 2005 Mar 1;174(5):2453-2455.

 

Larrick, JW, et al. Characterization of human hybridomas secreting antibody to tetanus toxoid. Proc Natl Acad Sci USA. 1993;80:6376-6380.

 

Lee R. et al. A high-throughput hybridoma selection method using Fluorometric Microvolume Assay Technology. J Biomol Screen. 2008;13(3):210-217.

 

Li J, et al. Human antibodies for immunotherapy development generated via a human B cell hybridoma technologyProc Natl Acad Sci U S A. 2006 Mar;103(10):3557-35662.

 

Lobito AA, et al. Murine insulin growth factor-like (IGFL) and human IGFL1 proteins are induced in inflammatory skin conditions and bind to a novel tumor necrosis factor receptor family member, IGFLR1.  J Biol Chem. 2011 May 27;286(21):18969-18981

 

Lobito AA, et al. An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodiesJ Immunol Methods. 2008 Jul;336(2):142-151.

 

Niedbala WG, Scott DI. A comparison of three methods for production of human hybridomas secreting autoantibodies. Hybridoma. 1998;17:299-304.

 

Neil GA, Zimmerman U. Electrofusion. Methods Enzymol. 1993;220:174-196.

 

O’Shannessy, DJ, et al. Novel antibody probes for the characterization of endosialin/TEM-1Oncotarget. 2016 Oct;7(43):69420-69435.

 

Schmidt, et al. CD19+ B lymphocytes are the major source of human antibody-secreting hybridomas generated by electrofusion. J Immunol Methods. 2001;255:93-102.

 

Shirahata S, et al. Cell hybridization, hybridomas, and human hybridomas. Meth Cell Biol. 1998;57:111-145.

 

Steenbakkers PG, van Meel FC, Olijve W. A new approach to the generation of human or murine antibody producing hybridomas. J Immunol Methods. 1992;152:69-77.

 

Sugasawara RJ, Cahoon BE, Karu AE. The influence of murine macrophage-conditioned medium on cloning efficiency, antibody synthesis, and growth rate of hybridomas. JImmunol Methods. 1985;79(2):263-75.

 

Trevor K. et al. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. CancerImmunol Immunother. 2004;53(3):705-714.

 

Vienken J, Zimmermann U. An improved electrofusion technique for production of mouse hybridoma cells. FEBS Lett. 1985;182:278-80.

 

Zhao Q, et. al. A novel function of CXCL10 in mediating monocyte production of proinflammatory cytokinesJ Leukoc Biol. 2017 Nov;102(5):1271-1280.

 

Zimmerman U, et al. Generation of a human monoclonal antibody to hepatitis C virus, JRA1 by activation of peripheral blood lymphocytes and hypo-osmolar electrofusion. Hum Antibodies Hybridomas. 1995;6:77-80.

 

Zuchero, YJY, Chen X, Bien-Ly N, Bumback D. Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodiesNeuron. 2016 Jan;89(1):70-82.